|Day Low/High||74.72 / 75.57|
|52 Wk Low/High||56.81 / 75.40|
As the U.S. and the world grow fatter, some investors are seeing green as they bulk up on stocks of companies on the front-lines of this 21st century Battle of the Bulge.
These mobile investment apps can get you up and trading fast, sometimes with no trading fees.
ABT is pointed up after trading in a choppy range since October.
Jim Cramer takes a closer look at Caterpillar, PG&E, Nio, Visa, Tenneco and more.
Jim Cramer says these giant hedge funds treat stocks like a plaything, and individual investors can lose out.
Abbott Labs has a good quarter and lifts its dividend but the stock slips.
The Dow Jones Industrial Average closed higher after solid earnings from several bellwethers helped to ease growth worries.
Abbott's fourth-quarter results capped off a terrific 2018.
Jim discusses what United Technologies' results mean for Honeywell, Abbott and Comcast earnings, his discussion with Viacom CEO Robert Bakish, how members need to view and attack this market environment and more!
Keeping an eye on the Senate shutdown vote and any trade discussion today, and watching key support levels on the SPX.
- Full-year 2018 sales growth of 11.6 percent; organic sales growth of 7.3 percent
U.S. stock futures rise following the previous session's sharp selloff amid fears of a slowing global economy; IBM jumps as fourth-quarter earnings and guidance top estimates; Procter & Gamble, Ford and Comcast report earnings Wednesday.
Abbott Laboratories revenue expected to rise 3% to $7.8 billion.
Jim discusses Johnson & Johnson's quarter, recaps Schlumberger's quarter, what he's looking for when Comcast and Abbott Labs report earnings, and more!
With approval of the TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™, Abbott is helping more physicians integrate ablation with 3D mapping to advance the treatment of people with atrial fibrillation
Jim Cramer's new rules of the road will help investors stay on course and avoid common mistakes. Plus, he's got your game plan.
U.S. markets pressed higher this week as earnings season got underway and on anticipation of a trade deal with China.
The kick will come from the Chinese capitulating because their economy is so weak.
LONG-TERM AGREEMENT BETWEEN JAPANESE RED CROSS SOCIETY AND ABBOTT BRINGS TOGETHER TWO GLOBAL LEADERS IN BLOOD AND PLASMA SCREENING, HELPING ENSURE A SAFE AND EFFICIENT BLOOD SUPPLY ACROSS JAPAN
Acquisition to further bolster Abbott's leading position in therapies for mitral valve disease, the most common type of heart valve ailment
- First and only minimally invasive, transcatheter treatment specifically approved for premature babies with a patent ductus, a life-threatening opening in their heart
- Abbott to supply rapid diagnostic tests critical for malaria detection and surveillance, technical expertise and funding support
They continue to work in this market and we believe can drive growth longer-term.
Mike Cintolo and Jim Woods saw their top picks for 2018 rise 81% and 75%, respectively.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.